Yili Chuannig Biotechnology Co Ltd
301301
Company Profile
Business description
Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid.
Contact
No. 516, Almatua Village
Yining Park, Horgos Economic Development Zone
Xinjiang
Ili835000
CHNT: +86 9998077777
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3,184
Stocks News & Analysis
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.50 | 11.90 | -0.13% |
| CAC 40 | 7,861.96 | 4.60 | 0.06% |
| DAX 40 | 24,262.22 | 44.85 | 0.19% |
| Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
| FTSE 100 | 9,136.94 | 0.62 | 0.01% |
| HKSE | 24,906.39 | 270.54 | -1.07% |
| NASDAQ | 21,129.67 | 31.38 | 0.15% |
| Nikkei 225 | 41,020.79 | 366.09 | 0.90% |
| NZX 50 Index | 12,836.39 | 19.58 | -0.15% |
| S&P 500 | 6,362.90 | 7.96 | -0.12% |
| S&P/ASX 200 | 8,749.30 | 7.10 | -0.08% |
| SSE Composite Index | 3,591.26 | 24.46 | -0.68% |